研究单位：[1]Pfizer's Upjohn has merged with Mylan to form Viatris Inc.[2]Guang'anmen hospital Beijing,Beijing,China,100053[3]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[4]The First Hospital of Fangshan District,Beijing Beijing,Beijing,China,102400[5]Chongqing Dianjiang People's Hospital Chongqing,Chongqing,China,400060[6]Xiamen Cardiovascular Hospital Xiamen,Fujian,China,361004[7]Shunde people's Hospital Foshan,Guangdong,China,528300[8]The Second Hospital of Hebei University Shijiazhuang,Hebei,China,050000[9]Heilongjiang Provincial Hospital Harbin,Heilongjiang,China,150030[10]The Peoples Hspital of Hebi City Hebi,Henan,China[11]Wuhan University - Renmin Hospital (Hubei General Hospital) Wuhan,Hubei,China,430060
研究目的：
The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
